Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

David Peter Steensma, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Suite D1B30 (Mayer 1B21)
450 Brookline Ave
Boston MA 02215
Phone617/632-5202
Fax617/632-7840

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Shampo MA, Kyle RA, Steensma DP. Horace magoun-neuroanatomist and neurophysiologist. Mayo Clin Proc. 2013 Apr; 88(4):e33.
    View in: PubMed
  2. Shampo MA, Kyle RA, Steensma DP. Hermann staudinger-founder of polymer chemistry. Mayo Clin Proc. 2013 Mar; 88(3):e23.
    View in: PubMed
  3. Tothova Z, Steensma DP, Ebert BL. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res. 2013 Apr 1; 19(7):1637-43.
    View in: PubMed
  4. Shampo MA, Kyle RA, Steensma DP. Elias james corey-nobel prize for retrosynthetic analysis. Mayo Clin Proc. 2013 Jan; 88(1):e7.
    View in: PubMed
  5. Shampo MA, Kyle RA, Steensma DP. Richard ernst-nobel prize for nuclear magnetic resonance spectroscopy. Mayo Clin Proc. 2012 Dec; 87(12):e109.
    View in: PubMed
  6. Steensma DP. Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors. Curr Hematol Malig Rep. 2012 Dec; 7(4):310-20.
    View in: PubMed
  7. Steensma DP, Viprakasit V, Kyle RA, Shampo MA. Prince wongsa dhiraj snid-thai physician and diplomat. Mayo Clin Proc. 2012 Nov; 87(11):e93.
    View in: PubMed
  8. Brierley CK, Morgan EA, Sprague JR, Odejide OO, Deangelo DJ, Steensma DP. An extreme example of focal bone marrow involvement in acute myeloid leukemia. Am J Hematol. 2013 Apr; 88(4):335-6.
    View in: PubMed
  9. Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2012 Dec; 25(4):443-51.
    View in: PubMed
  10. Shampo MA, Kyle RA, Steensma DP. Sidney Altman--Nobel laureate for work with RNA. Mayo Clin Proc. 2012 Oct; 87(10):e73.
    View in: PubMed
  11. Sekeres MA, Steensma DP. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol. 2012 Nov 20; 30(33):4061-3.
    View in: PubMed
  12. Kyle RA, Shampo MA, Steensma DP. Sir Brian Gerald Barratt-Boyes-pioneer cardiac surgeon. Mayo Clin Proc. 2012 Sep; 87(9):e65.
    View in: PubMed
  13. Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012 Dec; 36(12):1441-52.
    View in: PubMed
  14. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82.
    View in: PubMed
  15. Shampo MA, Kyle RA, Steensma DP. Catherine Verfaillie--stem cell researcher. Mayo Clin Proc. 2012 Aug; 87(8):e59.
    View in: PubMed
  16. Ruiz-Argüelles GJ, Gomez-Almaguer D, Steensma DP. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012 Sep; 87(9):941.
    View in: PubMed
  17. Shampo MA, Kyle RA, Steensma DP. William Shockley and the transistor. Mayo Clin Proc. 2012 Jun; 87(6):e43.
    View in: PubMed
  18. Steensma DP. Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1145-7.
    View in: PubMed
  19. Shampo MA, Kyle RA, Steensma DP. Charles F. Kettering-medical philanthropist and inventor. Mayo Clin Proc. 2012 May; 87(5):e35.
    View in: PubMed
  20. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012 Jun 10; 30(17):2134-9.
    View in: PubMed
  21. Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012; 5:18.
    View in: PubMed
  22. Shampo MA, Kyle RA, Steensma DP. Adolf Butenandt--Nobel Prize for chemistry. Mayo Clin Proc. 2012 Apr; 87(4):e27.
    View in: PubMed
  23. Jacobsen PB, Holland JC, Steensma DP. Caring for the whole patient: the science of psychosocial care. J Clin Oncol. 2012 Apr 10; 30(11):1151-3.
    View in: PubMed
  24. Motyckova G, Steensma DP. Why does my patient have lymphadenopathy or splenomegaly? Hematol Oncol Clin North Am. 2012 Apr; 26(2):395-408.
    View in: PubMed
  25. Shampo MA, Kyle RA, Steensma DP. Alexander Todd--British Nobel laureate. Mayo Clin Proc. 2012 Mar; 87(3):e19.
    View in: PubMed
  26. Shampo MA, Kyle RA, Steensma DP. Isidor Rabi-1944 Nobel laureate in physics. Mayo Clin Proc. 2012 Feb; 87(2):e11.
    View in: PubMed
  27. Shampo MA, Kyle RA, Steensma DP. Nikolay Basov--nobel prize for lasers and masers. Mayo Clin Proc. 2012 Jan; 87(1):e3.
    View in: PubMed
  28. Steensma DP. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol Oncol Clin North Am. 2011 Dec; 25(6):1235-53.
    View in: PubMed
  29. Shampo MA, Kyle RA, Steensma DP. Hans Geiger-German physicist and the Geiger counter. Mayo Clin Proc. 2011 Dec; 86(12):e54.
    View in: PubMed
  30. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119(2):569-72.
    View in: PubMed
  31. Shampo MA, Kyle RA, Steensma DP. Paul D. Boyer—Nobel prize for work on ATP synthase. Mayo Clin Proc. 2011 Nov; 86(11):e51.
    View in: PubMed
  32. Shampo MA, Kyle RA, Steensma DP. Walter Hess—Nobel Prize for work on the brain. Mayo Clin Proc. 2011 Oct; 86(10):E49.
    View in: PubMed
  33. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):635-47.
    View in: PubMed
  34. Shampo MA, Kyle RA, Steensma DP. Charles Townes—nobel laureate for maser-laser work. Mayo Clin Proc. 2011 Sep; 86(9):e48.
    View in: PubMed
  35. Sekeres MA, Steensma DP. A piece of my mind. The road warriors. JAMA. 2011 Aug 24; 306(8):805-6.
    View in: PubMed
  36. Shampo MA, Kyle RA, Steensma DP. Charles K. Kao—father of fiber optics. Mayo Clin Proc. 2011 Aug; 86(8):e45.
    View in: PubMed
  37. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):914-32.
    View in: PubMed
  38. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96(11):1619-26.
    View in: PubMed
  39. Steensma DP. Art of oncology: new voices wanted. J Clin Oncol. 2011 Sep 1; 29(25):3343-4.
    View in: PubMed
  40. Steensma DP, Stone RM. Lenalidomide in AML: del(5q) or who? Blood. 2011 Jul 21; 118(3):481-2.
    View in: PubMed
  41. Shampo MA, Kyle RA, Steensma DP. Albert Sabin--conqueror of poliomyelitis. Mayo Clin Proc. 2011 Jul; 86(7):e44.
    View in: PubMed
  42. Shampo MA, Kyle RA, Steensma DP. Frederick Soddy--pioneer in radioactivity. Mayo Clin Proc. 2011 Jun; 86(6):e39.
    View in: PubMed
  43. Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep. 2011 Jun; 6(2):136-44.
    View in: PubMed
  44. Shampo MA, Kyle RA, Steensma DP. Aleksandr Prokhorov--lasers and masers. Mayo Clin Proc. 2011 May; 86(5):e33.
    View in: PubMed
  45. Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011; 16(6):904-11.
    View in: PubMed
  46. Baumann Kreuziger LM, Wolanskyj AP, Hanson CA, Steensma DP. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. Eur J Haematol. 2011 Jun; 86(6):512-6.
    View in: PubMed
  47. Shampo MA, Kyle RA, Steensma DP. Susumu Tonegawa--Japan's first Nobel laureate in physiology or medicine. Mayo Clin Proc. 2011 Feb; 86(2):e14.
    View in: PubMed
  48. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011 Jan; 86(1):96-8.
    View in: PubMed
  49. Kyle RA, Steensma DP. History of multiple myeloma. Recent Results Cancer Res. 2011; 183:3-23.
    View in: PubMed
  50. Steensma DP. The role of iron chelation therapy for patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan; 9(1):65-75.
    View in: PubMed
  51. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011 Jan 1; 29(1):97-105.
    View in: PubMed
  52. Steensma DP, Kyle RA, Shampo MA. Abbie Lathrop, the "mouse woman of Granby": rodent fancier and accidental genetics pioneer. Mayo Clin Proc. 2010 Nov; 85(11):e83.
    View in: PubMed
  53. Loprinzi CL, Schapira L, Moynihan T, Kalemkerian GP, von Gunten C, Steensma D. Compassionate honesty. J Palliat Med. 2010 Oct; 13(10):1187-91.
    View in: PubMed
  54. Steensma DP, Kyle RA, Shampo MA. Walter Clement Noel—first patient described with sickle cell disease. Mayo Clin Proc. 2010 Oct; 85(10):e74-5.
    View in: PubMed
  55. Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010 Aug; 10(4):309-19.
    View in: PubMed
  56. Steensma DP. The scent of cancer. Ann Intern Med. 2010 Aug 3; 153(3):206-7.
    View in: PubMed
  57. Shampo MA, Kyle RA, Steensma DP. Stamp vignette on medical science. Robert F. Curl Jr-Nobel Laureate in Chemistry. Mayo Clin Proc. 2010 Aug; 85(8):e58.
    View in: PubMed
  58. Steensma DP. A cello for Michayla. J Clin Oncol. 2010 Oct 1; 28(28):4400-1.
    View in: PubMed
  59. Shampo MA, Kyle RA, Steensma DP. Edward L. Trudeau--founder of a sanatorium for treatment of tuberculosis. Mayo Clin Proc. 2010 Jul; 85(7):e48.
    View in: PubMed
  60. Steensma DP. P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes. Haematologica. 2010 Jul; 95(7):1229-30.
    View in: PubMed
  61. Steensma DP. Novel therapies for myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):423-41.
    View in: PubMed
  62. Calvin AD, Somers VK, Steensma DP, Rio Perez JA, van der Walt C, Fitz-Gibbon JM, Scott CG, Olson LJ. Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin. Eur J Heart Fail. 2010 Apr; 12(4):354-9.
    View in: PubMed
  63. Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):389-406.
    View in: PubMed
  64. Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol. 2010 Mar; 85(3):160-3.
    View in: PubMed
  65. Steensma DP. ACP Journal Club. Anemia was independently associated with mortality in very old persons. Ann Intern Med. 2009 Dec 15; 151(12):JC6-13.
    View in: PubMed
  66. Steensma DP. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res. 2009 Dec; 33 Suppl 2:S12-7.
    View in: PubMed
  67. Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, Maraganore DM, Steensma DP, Rocca WA. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology. 2009 Oct 27; 73(17):1381-7.
    View in: PubMed
  68. Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res. 2009 Oct 1; 69(19):7518-23.
    View in: PubMed
  69. Steensma DP. Out of this nettle, danger, we must pluck this flower, safety. Blood. 2009 Sep 17; 114(12):2364-5.
    View in: PubMed
  70. Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. Blood. 2009 Sep 24; 114(13):2575-80.
    View in: PubMed
  71. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009; (3):CD007303.
    View in: PubMed
  72. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
    View in: PubMed
  73. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009 May 2; 373(9674):1532-42.
    View in: PubMed
  74. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84(5):265-7.
    View in: PubMed
  75. Steensma DP. The Blood of the Lamb. J Clin Oncol. 2009 Jun 1; 27(16):2729-31.
    View in: PubMed
  76. Steensma DP. The ordinary miracle of cancer clinical trials. J Clin Oncol. 2009 Apr 10; 27(11):1737-9.
    View in: PubMed
  77. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203.
    View in: PubMed
  78. Steensma DP, Porcher JC, Litzow MR, Hogan WJ, Arora S, Van Laar ES. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine. Leuk Res. 2009 Jul; 33(7):e81-2.
    View in: PubMed
  79. Li C, Di Pierro E, Brancaleoni V, Cappellini MD, Steensma DP. A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria. Clin Chem Lab Med. 2009; 47(1):44-6.
    View in: PubMed
  80. Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009; 645-55.
    View in: PubMed
  81. Steensma DP. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe? Am J Hematol. 2009 Jan; 84(1):3-5.
    View in: PubMed
  82. Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol. 2009 Mar; 144(6):809-17.
    View in: PubMed
  83. Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res. 2009 Sep; 33(9):1158-63.
    View in: PubMed
  84. Steensma DP, Tefferi A. Incremental gains and a long road ahead in MDS. Oncology (Williston Park). 2008 Nov 15; 22(12):1352, 1358, 1360.
    View in: PubMed
  85. Kumar N, Sandroni P, Steensma DP, Luthra HS, Habermann TM. Polyradiculopathy due to methotrexate-induced ebv-associated lymphoproliferative disorder. Neurology. 2008 Nov 11; 71(20):1644-5.
    View in: PubMed
  86. Knoll BM, Letendre L, Steensma DP. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2008 Nov; 83(11):881-3.
    View in: PubMed
  87. Steensma DP, Shampo MA, Kyle RA. George Herman "Babe" Ruth Jr: baseball star and early participant in a cancer clinical trial. Mayo Clin Proc. 2008 Nov; 83(11):1262.
    View in: PubMed
  88. Chen D, Hoyer JD, Ketterling RP, Tefferi A, Steensma DP, Holtan SG, Santana-Davila R, Porrata LF, Dewald GW, Hanson CA. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q. Leukemia. 2009 Apr; 23(4):796-800.
    View in: PubMed
  89. Baumann Kreuziger LM, Steensma DP. RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. Am J Hematol. 2008 Oct; 83(10):822-3.
    View in: PubMed
  90. Steensma DP. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol. 2008 Sep; 83(9):693-4.
    View in: PubMed
  91. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol. 2008 Sep; 83(9):708-13.
    View in: PubMed
  92. Caudill JS, Imran H, Porcher JC, Steensma DP. Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH. Haematologica. 2008 Oct; 93(10):1582-4.
    View in: PubMed
  93. Gangat N, Porcher JC, Steensma DP. Absence of frataxin mutations in refractory anemia with ring sideroblasts (RARS). Leuk Res. 2009 Apr; 33(4):586-7.
    View in: PubMed
  94. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol. 2008 Aug; 83(8):611-3.
    View in: PubMed
  95. Dronca RS, Steensma DP. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia. Nat Clin Pract Oncol. 2008 Sep; 5(9):504-5.
    View in: PubMed
  96. Steensma DP. The mosaic of myeloid neoplasia: implications for classification. Leuk Lymphoma. 2008 Jul; 49(7):1228-9.
    View in: PubMed
  97. Steensma DP. The art of oncology: when the tumor is not the target. Don't mention it. J Clin Oncol. 2008 Jun 20; 26(18):3083-4.
    View in: PubMed
  98. Steensma DP. Review: epoetin and darbepoetin reduce need for blood transfusions but increase risk for thrombosis in patients with cancer. ACP J Club. 2008 Jun 17; 148(4):7.
    View in: PubMed
  99. Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk Res. 2008 Dec; 32(12):1927-30.
    View in: PubMed
  100. Gibbons RJ, Wada T, Fisher CA, Malik N, Mitson MJ, Steensma DP, Fryer A, Goudie DR, Krantz ID, Traeger-Synodinos J. Mutations in the chromatin-associated protein ATRX. Hum Mutat. 2008 Jun; 29(6):796-802.
    View in: PubMed
  101. Caudill JS, Porcher JC, Steensma DP. Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk Lymphoma. 2008 May; 49(5):989-93.
    View in: PubMed
  102. Steensma DP. Investment analysts and the American Society of Hematology. Blood. 2008 Jul 1; 112(1):29-33.
    View in: PubMed
  103. Steensma DP. A premature obituary for erythropoietin analogues. Lancet Oncol. 2008 Apr; 9(4):316.
    View in: PubMed
  104. Hanson CA, Steensma DP, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, Zou Y, Knudson RA, Van Dyke DL, Ketterling RP. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol. 2008 Mar; 129(3):478-85.
    View in: PubMed
  105. Steensma DP, Tefferi A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood. 2008 Feb 1; 111(3):1748.
    View in: PubMed
  106. Palmer SR, Tefferi A, Hanson CA, Steensma DP. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. Br J Haematol. 2008 Mar; 140(6):722-5.
    View in: PubMed
  107. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol. 2008 Mar 1; 26(7):1022-4.
    View in: PubMed
  108. Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008 May; 32(5):691-8.
    View in: PubMed
  109. Steensma DP. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. J Support Oncol. 2007 Nov-Dec; 5(10):471-3.
    View in: PubMed
  110. Steensma DP, Porcher JC, Hanson CA, Lathrop CL, Hoyer JD, Lasho TA, Tefferi A, Higgs DR. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol. 2007 Nov; 139(3):439-42.
    View in: PubMed
  111. Steensma DP. Exacerbation of asthma by Florida "red tide" during an ocean sailing trip. Mayo Clin Proc. 2007 Sep; 82(9):1128-30.
    View in: PubMed
  112. White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry. Platelets. 2007 Sep; 18(6):436-50.
    View in: PubMed
  113. Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leuk Res. 2008 Mar; 32(3):407-11.
    View in: PubMed
  114. Steensma DP, Friday BB. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leuk Lymphoma. 2007 Aug; 48(8):1628-9.
    View in: PubMed
  115. Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007 Aug; 82(8):958-66.
    View in: PubMed
  116. Steensma DP. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia. Haematologica. 2007 Jun; 92(6):723-7.
    View in: PubMed
  117. White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia I ultrastructure. Platelets. 2007 Jun; 18(4):273-83.
    View in: PubMed
  118. Steensma DP. Erythropoiesis stimulating agents. BMJ. 2007 Mar 31; 334(7595):648-9.
    View in: PubMed
  119. Steensma DP. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. J Clin Oncol. 2007 Mar 20; 25(9):1148; author reply 1148-9.
    View in: PubMed
  120. Loprinzi CL, Barton DL, Jatoi A, Sloan J, Martenson J, Steensma D, Rao R, Novotny P, Sood A, Grothey A, Minasian L, Windschitl H. Symptom control trials: a 20-year experience. J Support Oncol. 2007 Mar; 5(3):119-25, 128.
    View in: PubMed
  121. Kreuziger LM, Porcher JC, Ketterling RP, Steensma DP. An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. Leuk Res. 2007 Aug; 31(8):1145-8.
    View in: PubMed
  122. Shampo MA, Kyle RA, Steensma DP. Leopold Ruzicka--1939 Nobel Prize in chemistry. Mayo Clin Proc. 2007 Jan; 82(1):1p preceeding table of contents.
    View in: PubMed
  123. Steensma DP, Kyle RA. A history of the kidney in plasma cell disorders. Contrib Nephrol. 2007; 153:5-24.
    View in: PubMed
  124. Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park). 2007 Jan; 21(1):43-54; discussion 57-8, 62.
    View in: PubMed
  125. Caudill JS, Sood R, Zehnder JL, Pruthi RK, Steensma DP. Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q. J Thromb Haemost. 2007 Mar; 5(3):626-8.
    View in: PubMed
  126. Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007 Mar 15; 109(6):2618-21.
    View in: PubMed
  127. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica. 2006 Dec; 91(12 Suppl):ECR57.
    View in: PubMed
  128. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006 Nov; 135(3):405-7.
    View in: PubMed
  129. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia. 2006 Nov; 20(11):2063-4.
    View in: PubMed
  130. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006 Sep; 8(4):397-411; quiz 526.
    View in: PubMed
  131. Knox SK, Kurtin PJ, Steensma DP. Isolated splenic sinus histiocytosis (Rosai-Dorfman disease) in association with myelodysplastic syndrome. J Clin Oncol. 2006 Aug 20; 24(24):4027-8.
    View in: PubMed
  132. Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006 Oct; 20(10):1800-8.
    View in: PubMed
  133. Steensma DP, Hecksel KA, Porcher JC, Lasho TL. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Leuk Res. 2007 May; 31(5):623-8.
    View in: PubMed
  134. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10):3472-6.
    View in: PubMed
  135. Thurmes PJ, Steensma DP. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol. 2006 Jul; 77(1):57-60.
    View in: PubMed
  136. Shampo MA, Kyle RA, Steensma DP. William Murphy--Nobel Prize for the treatment of pernicious anemia. Mayo Clin Proc. 2006 Jun; 81(6):726.
    View in: PubMed
  137. Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol. 2006 Jun; 133(6):638-41.
    View in: PubMed
  138. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006 Jun; 20(6):971-8.
    View in: PubMed
  139. Steensma DP, Loprinzi CL. Epoetin alfa and darbepoetin alfa go head to head. J Clin Oncol. 2006 May 20; 24(15):2233-6.
    View in: PubMed
  140. Steensma DP. Working against the grain. Ann Intern Med. 2006 May 2; 144(9):697-8.
    View in: PubMed
  141. Shampo MA, Kyle RA, Steensma DP. Stamp vignette on medical science. William F. Giauque--Nobel Prize for low-temperature research. Mayo Clin Proc. 2006 May; 81(5):587.
    View in: PubMed
  142. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006 Mar 1; 24(7):1079-89.
    View in: PubMed
  143. Steensma DP, Tefferi A. Blood vessels everywhere, but so few cells to fill them. Leuk Lymphoma. 2006 Mar; 47(3):377-8.
    View in: PubMed
  144. Costa DB, Fisher CA, Miller KB, Pihan GA, Steensma DP, Gibbons RJ, Higgs DR. A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. Eur J Haematol. 2006 May; 76(5):432-5, 453.
    View in: PubMed
  145. Steensma DP, Pardanani A, Stevenson WS, Hoyt R, Kiu H, Grigg AP, Szer J, Juneja S, Hilton DJ, Alexander WS, Roberts AW. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Blood. 2006 Feb 15; 107(4):1733-5; author reply 1735.
    View in: PubMed
  146. Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma. 2006 Feb; 47(2):177-94.
    View in: PubMed
  147. Steensma DP. Luis Walter Alvarez: another "Mayo-trained" Nobel Laureate. Mayo Clin Proc. 2006 Feb; 81(2):241-4.
    View in: PubMed
  148. Steensma DP. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006 Oct; 30(10):1227-33.
    View in: PubMed
  149. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan; 81(1):104-30.
    View in: PubMed
  150. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005 Dec; 19(12):2195-202.
    View in: PubMed
  151. Nelson ME, Thurmes PJ, Hoyer JD, Steensma DP. A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome. Haematologica. 2005 Nov; 90(11):1463-70.
    View in: PubMed
  152. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005 Nov; 131(3):320-8.
    View in: PubMed
  153. Shampo MA, Kyle RA, Steensma DP. Sir Charles Sherrington--"The William Harvey of the nervous system". Mayo Clin Proc. 2005 Oct; 80(10):1266.
    View in: PubMed
  154. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005 Oct; 131(2):166-71.
    View in: PubMed
  155. Loprinzi C, Steensma D. The questions of prognosis. J Support Oncol. 2005 Sep-Oct; 3(5):340-1.
    View in: PubMed
  156. Steensma DP, Witzig TE. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer? Nat Clin Pract Oncol. 2005 Sep; 2(9):444-5.
    View in: PubMed
  157. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol. 2005 Sep 1; 23(25):5865-8.
    View in: PubMed
  158. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc. 2005 May; 80(5):681-98.
    View in: PubMed
  159. Steensma DP. Polycythemia vera: plethora, from prehistory to present. Curr Hematol Rep. 2005 May; 4(3):230-4.
    View in: PubMed
  160. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15; 106(4):1207-9.
    View in: PubMed
  161. Steensma DP, Shampo MA, Kyle RA. Cecilia Makiwane--pioneer African nurse. Mayo Clin Proc. 2005 Apr; 80(4):449.
    View in: PubMed
  162. Shanafelt TD, Novotny P, Johnson ME, Zhao X, Steensma DP, Lacy MQ, Rubin J, Sloan J. The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. Oncology. 2005; 68(1):23-32.
    View in: PubMed
  163. Steensma DP. Down syndrome in Down House: trisomy 21, GATA1 mutations, and Charles Darwin. Blood. 2005 Mar 15; 105(6):2614-6.
    View in: PubMed
  164. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):47-53.
    View in: PubMed
  165. Steensma DP. Northwoods elegy. Ann Intern Med. 2004 Oct 5; 141(7):573-4.
    View in: PubMed
  166. Shampo MA, Kyle RA, Steensma DP. Ferid Murad--1998 Nobel laureate for nitric oxide research. Mayo Clin Proc. 2004 Oct; 79(10):1230.
    View in: PubMed
  167. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005 Jan 15; 105(2):443-52.
    View in: PubMed
  168. Fisher C, Steensma D, Janmohamed R, Kaczmarski R, Reilly JT, Vyas P. Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis. Br J Haematol. 2004 Sep; 126(5):750-2.
    View in: PubMed
  169. Steensma DP. Myelodysplasia, megakaryocytes, and methylation. Leuk Res. 2004 Aug; 28(8):775-6.
    View in: PubMed
  170. Steensma DP. Reassurance. J Clin Oncol. 2004 Aug 1; 22(15):3196-8.
    View in: PubMed
  171. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep. 2004 Jul; 6(4):297-304.
    View in: PubMed
  172. Steensma DP. The symbol of modern medicine. Ann Intern Med. 2004 Feb 17; 140(4):311; author reply 311-2.
    View in: PubMed
  173. Steensma DP. Enough already of the word "robust"! Blood. 2004 Jan 15; 103(2):746-7.
    View in: PubMed
  174. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood. 2004 Mar 15; 103(6):2019-26.
    View in: PubMed
  175. Steensma DP, Viprakasit V, Hendrick A, Goff DK, Leach J, Gibbons RJ, Higgs DR. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. Blood. 2004 Feb 15; 103(4):1518-20.
    View in: PubMed
  176. Mesa RA, Steensma DP, Hoyer J, Ketterling RP. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. Br J Haematol. 2003 Oct; 123(2):366-7.
    View in: PubMed
  177. Steensma DP, Mesa RA, Reeder TL, Tefferi A, Kaufmann SH. Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow. Haematologica. 2003 Sep; 88(9):1072-4.
    View in: PubMed
  178. Steensma DP, Tefferi A, Li CY. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res. 2003 Sep; 27(9):775-82.
    View in: PubMed
  179. Steensma DP. The In-Training Examination in Internal Medicine. Ann Intern Med. 2003 Jun 17; 138(12):1009; author reply 1010-1.
    View in: PubMed
  180. Daugherty CK, Steensma DP. Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2003 May 1; 21(9 Suppl):42s-45s.
    View in: PubMed
  181. Steensma DP. The narrow path. J Clin Oncol. 2003 May 1; 21(9 Suppl):57s-60s; discussion 60s.
    View in: PubMed
  182. Steensma DP. Submitting to autonomy. J Clin Oncol. 2003 May 1; 21(9 Suppl):62s-63s.
    View in: PubMed
  183. Steensma DP. The chronic myeloproliferative disorders: an historical perspective. Curr Hematol Rep. 2003 May; 2(3):221-30.
    View in: PubMed
  184. Steensma DP. Why me? J Clin Oncol. 2003 May 1; 21(9 Suppl):64s-66s.
    View in: PubMed
  185. Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res. 2003 Mar; 27(3):235-42.
    View in: PubMed
  186. Steensma DP. The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss. Mayo Clin Proc. 2003 Feb; 78(2):221-2.
    View in: PubMed
  187. Steensma DP. "Pawn Ball Megakaryocytes": from the marvellous medici and dear Old Saint Nick to the unsanctified marrow of myelodysplasia. Hematology. 2003 Feb; 8(1):11-8.
    View in: PubMed
  188. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003 Feb; 27(2):95-120.
    View in: PubMed
  189. Steensma DP. Eureka moments. Pharos Alpha Omega Alpha Honor Med Soc. 2003; 66(4):43.
    View in: PubMed
  190. Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003; 85:323-32.
    View in: PubMed
  191. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1; 101(7):2534-41.
    View in: PubMed
  192. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003 Mar 15; 101(6):2156-8.
    View in: PubMed
  193. Steensma DP. The other résumé. Ann Intern Med. 2002 Oct 1; 137(7):623.
    View in: PubMed
  194. Steensma DP. John Calvin and Michael Servetus: tragic clash of reformer and radical physician. Scalpel Tongs. 2002 Oct-Dec; 46(1):14-9.
    View in: PubMed
  195. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 Sep; 118(3):813-6.
    View in: PubMed
  196. Daugherty CK, Steensma DP. Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2002 Jun 1; 20(11):2752-5.
    View in: PubMed
  197. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99(10):3854-6.
    View in: PubMed
  198. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002 Mar 15; 99(6):2252-4.
    View in: PubMed
  199. Steensma DP. Why me? J Clin Oncol. 2002 Feb 1; 20(3):873-5.
    View in: PubMed
  200. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002; 108(2):55-65.
    View in: PubMed
  201. Steensma DP, Tefferi A. Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1229-34.
    View in: PubMed
  202. Steensma DP, Harrison CN, Tefferi A. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1243-53.
    View in: PubMed
  203. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001 Oct; 25(10):829-38.
    View in: PubMed
  204. Steensma DP, Letendre L, Tefferi A. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. Blood. 2001 May 15; 97(10):3321-2.
    View in: PubMed
  205. Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001 Apr 15; 97(8):2522-3.
    View in: PubMed
  206. Steensma DP. The narrow path. J Clin Oncol. 2001 Apr 1; 19(7):2102-5.
    View in: PubMed
  207. Steensma DP, Hoyer JD, Fairbanks VF. Hereditary red blood cell disorders in middle eastern patients. Mayo Clin Proc. 2001 Mar; 76(3):285-93.
    View in: PubMed
  208. Steensma DP. "Congo" red: out of Africa? Arch Pathol Lab Med. 2001 Feb; 125(2):250-2.
    View in: PubMed
  209. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001 Feb; 25(2):183-5.
    View in: PubMed
  210. Steensma DP. Submitting to autonomy. J Clin Oncol. 2000 Nov 1; 18(21):3736-7.
    View in: PubMed
  211. Steensma DP, Loprinzi CL. The art and science of prognosis in patients with advanced cancer. Eur J Cancer. 2000 Oct; 36(16):2025-7.
    View in: PubMed
  212. Steensma DP. Sister (Mary) Joseph's nodule. Ann Intern Med. 2000 Aug 1; 133(3):237.
    View in: PubMed
  213. Steensma DP, Tefferi A, Weiler CR. Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis. Mayo Clin Proc. 2000 Aug; 75(8):853-5.
    View in: PubMed
  214. Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clin Proc. 2000 Jul; 75(7):723-32.
    View in: PubMed
  215. Steensma DP, Morice WG. Littoral cell angioma associated with portal hypertension and resected colon cancer. Acta Haematol. 2000; 104(2-3):131-4.
    View in: PubMed
  216. Steensma DP, Witzig TE. Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign. Br J Haematol. 1999 Nov; 107(2):463-4.
    View in: PubMed
  217. Steensma DP. Fifty years of Tart cells. Mayo Clin Proc. 1999 Sep; 74(9):936-8.
    View in: PubMed
  218. Steensma DP, Matteson EL. 80-year-old woman with dizziness. Mayo Clin Proc. 1997 Aug; 72(8):781-4.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Steensma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (706) concept(s)
_
Co-Authors
See all (13) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_